CA2212552C - Hepatitis b vaccine - Google Patents

Hepatitis b vaccine Download PDF

Info

Publication number: CA2212552C
Authority: CA; Canada
Prior art keywords: hepatitis; vaccine composition; hbsag; antigen; vaccine
Prior art date: 1995-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002212552A

Other languages

English (en)

French (fr)

Other versions

CA2212552A1 (en

Inventor

Pierre Hauser

Nathalie Marie-Josephe Claude Garcon

Pierre Desmons

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

SmithKline Beecham Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-25

Filing date

1996-02-15

Publication date

2006-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2212552(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-15 Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA

1996-09-06 Publication of CA2212552A1 publication Critical patent/CA2212552A1/en

2006-07-11 Application granted granted Critical

2006-07-11 Publication of CA2212552C publication Critical patent/CA2212552C/en

2016-02-15 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229940124736 hepatitis-B vaccine Drugs 0.000 title description 7
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title description 4
229960005486 vaccine Drugs 0.000 claims abstract description 42
239000000203 mixture Substances 0.000 claims abstract description 41
239000000427 antigen Substances 0.000 claims abstract description 34
102000036639 antigens Human genes 0.000 claims abstract description 34
108091007433 antigens Proteins 0.000 claims abstract description 34
208000002672 hepatitis B Diseases 0.000 claims abstract description 28
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 14
229940035032 monophosphoryl lipid a Drugs 0.000 claims abstract description 13
208000006454 hepatitis Diseases 0.000 claims description 8
231100000283 hepatitis Toxicity 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
229940029583 inactivated polio vaccine Drugs 0.000 claims description 6
230000003472 neutralizing effect Effects 0.000 claims description 6
241000700721 Hepatitis B virus Species 0.000 claims description 5
206010043376 Tetanus Diseases 0.000 claims description 5
206010013023 diphtheria Diseases 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
201000005702 Pertussis Diseases 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
238000011282 treatment Methods 0.000 claims description 4
102100031673 Corneodesmosin Human genes 0.000 claims description 3
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 3
241000282412 Homo Species 0.000 claims description 3
101710137302 Surface antigen S Proteins 0.000 claims description 3
208000005252 hepatitis A Diseases 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
230000004224 protection Effects 0.000 claims description 3
241000606768 Haemophilus influenzae Species 0.000 claims description 2
208000000474 Poliomyelitis Diseases 0.000 claims description 2
229940096437 Protein S Drugs 0.000 claims description 2
108010031318 Vitronectin Proteins 0.000 claims description 2
239000011246 composite particle Substances 0.000 claims description 2
229940047650 haemophilus influenzae Drugs 0.000 claims description 2
230000006698 induction Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims 2
201000009906 Meningitis Diseases 0.000 claims 1
125000003275 alpha amino acid group Chemical group 0.000 claims 1
238000009472 formulation Methods 0.000 abstract description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000002245 particle Substances 0.000 description 8
229960002520 hepatitis vaccine Drugs 0.000 description 6
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 6
229960004906 thiomersal Drugs 0.000 description 6
230000004044 response Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229940124884 Engerix-B Drugs 0.000 description 4
229940001442 combination vaccine Drugs 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
206010019799 Hepatitis viral Diseases 0.000 description 3
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
201000001862 viral hepatitis Diseases 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
229940001007 aluminium phosphate Drugs 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229940021747 therapeutic vaccine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229940124914 Havrix Drugs 0.000 description 1
206010057212 Hepatitis viral infections Diseases 0.000 description 1
229940124915 Infanrix Drugs 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007689 endotoxicity Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229910001679 gibbsite Inorganic materials 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
229960005323 phenoxyethanol Drugs 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002212552A 1995-02-25 1996-02-15 Hepatitis b vaccine Expired - Fee Related CA2212552C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9503863.4A GB9503863D0 (en)	1995-02-25	1995-02-25	Vaccine compositions
GB9503863.4		1995-02-25
PCT/EP1996/000681 WO1996026741A1 (en)	1995-02-25	1996-02-15	Hepatitis b vaccine

Publications (2)

Publication Number	Publication Date
CA2212552A1 CA2212552A1 (en)	1996-09-06
CA2212552C true CA2212552C (en)	2006-07-11

Family

ID=10770292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002212552A Expired - Fee Related CA2212552C (en)	1995-02-25	1996-02-15	Hepatitis b vaccine

Country Status (36)

Country	Link
US (1)	US5972346A (es)
EP (1)	EP0810877B1 (es)
JP (1)	JP3881015B2 (es)
KR (1)	KR100365373B1 (es)
CN (1)	CN1101225C (es)
AP (1)	AP766A (es)
AR (1)	AR002279A1 (es)
AT (1)	ATE209045T1 (es)
AU (1)	AU695921B2 (es)
BG (1)	BG101851A (es)
BR (1)	BR9607458A (es)
CA (1)	CA2212552C (es)
CZ (1)	CZ288417B6 (es)
DE (1)	DE69617211T2 (es)
DK (1)	DK0810877T3 (es)
EA (1)	EA199700126A1 (es)
ES (1)	ES2166879T3 (es)
FI (1)	FI118118B (es)
GB (1)	GB9503863D0 (es)
HK (1)	HK1004117A1 (es)
HU (1)	HU224832B1 (es)
IL (1)	IL117249A (es)
MA (1)	MA23814A1 (es)
MX (1)	MX9706450A (es)
MY (1)	MY113428A (es)
NO (1)	NO319394B1 (es)
NZ (1)	NZ302674A (es)
OA (1)	OA10612A (es)
PL (1)	PL182679B1 (es)
PT (1)	PT810877E (es)
SA (1)	SA96160633B1 (es)
SK (1)	SK115097A3 (es)
TR (1)	TR199700849T1 (es)
TW (1)	TW467745B (es)
WO (1)	WO1996026741A1 (es)
ZA (1)	ZA961460B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6620414B2 (en) *	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr)	1993-10-22	1996-01-12	Pasteur Institut	Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) *	1995-02-25	2002-12-03	Smithkline Beecham Biologicals S.A.	Hepatitis B vaccine
US20010014331A1 (en) *	1996-11-07	2001-08-16	Smithkline Beecham Biologicals S.A.	Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en)	1998-05-01	2003-03-13	Smithkline Beecham Biologicals S.A.	Novel composition
GB9809507D0 (en) *	1998-05-01	1998-07-01	Smithkline Beecham Biolog	Novel composition
ES2272069T3 (es)	1998-05-22	2007-04-16	Ottawa Health Research Institute	Metodos y productos para inducir inmunidad en mucosas.
US6306404B1 (en)	1998-07-14	2001-10-23	American Cyanamid Company	Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1126876B1 (en) *	1998-10-16	2007-03-21	GlaxoSmithKline Biologicals S.A.	Adjuvant systems and vaccines
CU22871A1 (es) *	1998-12-02	2003-10-21	Ct Ingenieria Genetica Biotech	Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP1140155A4 (en) *	1998-12-23	2004-11-03	Merck & Co Inc	IMPROVED RECOMBINATION HEPATITIS B ENVELOPE ANTIGEN
EP2322210A1 (en)	1999-04-19	2011-05-18	GlaxoSmithKline Biologicals S.A.	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6635261B2 (en)	1999-07-13	2003-10-21	Wyeth Holdings Corporation	Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) *	2002-01-24	2005-02-23	Ct Ingenieria Genetica Biotech	Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2006215419B2 (en) *	2005-02-16	2012-03-08	Novartis Vaccines And Diagnostics, Inc.	Adjuvant composition comprising aluminium phosphate and 3D-MPL
AP2745A (en) *	2005-08-02	2013-09-30	Novartis Vaccines & Diagnostic	Reducing interference between oil-containing adjuvants and surfactant-containing antigens
NZ592713A (en)	2005-11-04	2012-12-21	Novartis Vaccines & Diagnostic	Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
US20090304742A1 (en)	2005-11-04	2009-12-10	Novartis Vaccines And Diagnostics Srl	Influenza vaccines with reduced amount of emulsion adjuvant
PT1951299E (pt)	2005-11-04	2012-02-28	Novartis Vaccines & Diagnostic	Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
EP2368572B1 (en)	2005-11-04	2020-03-04	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN100415294C (zh) *	2005-12-23	2008-09-03	中国农业大学	一种治疗和/或预防乙肝的药物
KR20110110853A (ko)	2006-01-27	2011-10-07	노파르티스 파르마 아게	적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
CA2646539A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja)	2006-03-24	2009-09-24	ノバルティスヴァクシンズアンドダイアグノスティクスゲーエムベーハーアンドカンパニーカーゲー	冷蔵しないインフルエンザワクチンの保存
EP1862176A1 (de) *	2006-05-31	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) *	2006-06-01	2007-12-05	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Ein Verfahren zur Herstellung einer Impfzusammensetzung
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
AU2007297178B2 (en)	2006-09-11	2014-07-24	Novartis Ag	Making influenza virus vaccines without using eggs
CA2671629C (en)	2006-12-06	2017-08-15	Novartis Ag	Vaccines including antigen from four strains of influenza virus
AU2008269439B2 (en)	2007-06-27	2013-12-19	Novartis Ag	Low-additive influenza vaccines
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en)	2007-12-24	2014-07-24	Novartis Ag	Assays for adsorbed influenza vaccines
AR077757A1 (es)	2009-07-15	2011-09-21	Novartis Ag	Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
WO2012103361A1 (en)	2011-01-26	2012-08-02	Novartis Ag	Rsv immunization regimen
US9452212B2 (en)	2011-04-14	2016-09-27	Dynavax Technologies Corporation	Methods and compositions for eliciting an immune response against hepatitis B virus
HUE034673T2 (en)	2011-05-13	2018-02-28	Glaxosmithkline Biologicals Sa	Pre-fusion rsv f antigens
WO2016207853A2 (en)	2015-06-26	2016-12-29	Seqirus UK Limited	Antigenically matched influenza vaccines
US12128100B2 (en)	2018-11-13	2024-10-29	Variation Biotechnologies Inc.	Immunogenic compositions for treatment of Hepatitis B

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
DE69031556T2 (de) *	1989-07-25	1998-05-14	Smithkline Beecham Biologicals S.A., Rixensart	Antigene sowie Verfahren zu deren Herstellung
JP3307392B2 (ja) *	1991-05-29	2002-07-24	オリジン・メドシステムズ・インク	内視鏡による手術用の器官後退装置
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2118963T3 (es) *	1992-05-23	1998-10-01	Smithkline Beecham Biolog	Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
ATE204762T1 (de) *	1993-03-23	2001-09-15	Smithkline Beecham Biolog	3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9311536D0 (en) *	1993-06-04	1993-07-21	Unilever Plc	Hot soluble low density extractable food product

1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/ko not_active IP Right Cessation
- 1996-02-15 EP EP96904814A patent/EP0810877B1/en not_active Expired - Lifetime
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/cs not_active IP Right Cessation
- 1996-02-15 ES ES96904814T patent/ES2166879T3/es not_active Expired - Lifetime
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/xx unknown
- 1996-02-15 CN CN96192146A patent/CN1101225C/zh not_active Expired - Fee Related
- 1996-02-15 SK SK1150-97A patent/SK115097A3/sk unknown
- 1996-02-15 EA EA199700126A patent/EA199700126A1/ru unknown
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 PL PL96321966A patent/PL182679B1/pl unknown
- 1996-02-15 PT PT96904814T patent/PT810877E/pt unknown
- 1996-02-15 BR BR9607458A patent/BR9607458A/pt not_active IP Right Cessation
- 1996-02-15 DE DE69617211T patent/DE69617211T2/de not_active Expired - Lifetime
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en active IP Right Grant
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 JP JP52598896A patent/JP3881015B2/ja not_active Expired - Fee Related
- 1996-02-15 DK DK96904814T patent/DK0810877T3/da active
- 1996-02-15 HU HU9801242A patent/HU224832B1/hu not_active IP Right Cessation
- 1996-02-15 NZ NZ302674A patent/NZ302674A/xx not_active IP Right Cessation
- 1996-02-15 AT AT96904814T patent/ATE209045T1/de active
- 1996-02-22 AR ARP960101469A patent/AR002279A1/es active IP Right Grant
- 1996-02-23 IL IL11724996A patent/IL117249A/xx not_active IP Right Cessation
- 1996-02-23 ZA ZA961460A patent/ZA961460B/xx unknown
- 1996-02-23 MA MA24171A patent/MA23814A1/fr unknown
- 1996-02-26 TW TW085102154A patent/TW467745B/zh not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/ar unknown
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 FI FI973457A patent/FI118118B/fi not_active IP Right Cessation
- 1997-08-22 MX MX9706450A patent/MX9706450A/es unknown
- 1997-08-22 NO NO19973873A patent/NO319394B1/no not_active IP Right Cessation
- 1997-08-25 BG BG101851A patent/BG101851A/xx unknown
1998
- 1998-04-28 HK HK98103600A patent/HK1004117A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP9801242A1 (hu)	1998-08-28
IL117249A (en)	2000-11-21
KR100365373B1 (ko)	2003-07-07
JP3881015B2 (ja)	2007-02-14
AP9701060A0 (en)	1997-10-31
KR19980702480A (ko)	1998-07-15
PL182679B1 (pl)	2002-02-28
DK0810877T3 (da)	2002-02-25
CN1176604A (zh)	1998-03-18
EP0810877B1 (en)	2001-11-21
AR002279A1 (es)	1998-03-11
EA199700126A1 (ru)	1998-02-26
IL117249A0 (en)	1996-06-18
WO1996026741A1 (en)	1996-09-06
BR9607458A (pt)	1998-06-30
DE69617211T2 (de)	2002-07-25
MA23814A1 (fr)	1996-10-01
AP766A (en)	1999-09-17
PT810877E (pt)	2002-04-29
MX9706450A (es)	1998-07-31
NO319394B1 (no)	2005-08-08
OA10612A (en)	2002-08-29
HUP9801242A3 (en)	2000-08-28
SA96160633B1 (ar)	2005-10-15
BG101851A (en)	1998-04-30
EP0810877A1 (en)	1997-12-10
GB9503863D0 (en)	1995-04-19
FI973457A0 (fi)	1997-08-22
DE69617211D1 (en)	2002-01-03
AU695921B2 (en)	1998-08-27
TR199700849T1 (xx)	1998-01-21
NO973873D0 (no)	1997-08-22
HK1004117A1 (en)	1998-11-20
CZ267497A3 (cs)	1998-02-18
HU224832B1 (en)	2006-03-28
MY113428A (en)	2002-02-28
ZA961460B (en)	1996-08-29
AU4878096A (en)	1996-09-18
PL321966A1 (en)	1998-01-05
NO973873L (no)	1997-08-22
FI973457A (fi)	1997-08-22
ATE209045T1 (de)	2001-12-15
FI118118B (fi)	2007-07-13
US5972346A (en)	1999-10-26
ES2166879T3 (es)	2002-05-01
CN1101225C (zh)	2003-02-12
SK115097A3 (en)	1998-02-04
NZ302674A (en)	1999-01-28
CZ288417B6 (en)	2001-06-13
CA2212552A1 (en)	1996-09-06
TW467745B (en)	2001-12-11
JPH11501018A (ja)	1999-01-26

Publication	Publication Date	Title
CA2212552C (en)	2006-07-11	Hepatitis b vaccine
CA2132833C (en)	2007-03-06	Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
EP0689454B1 (en)	1997-09-10	Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
WO1996040242A1 (en)	1996-12-19	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
IL105770A (en)	1998-08-16	Concentrated vaccine preparations containing supernatant of hepatitis (GASBH)
EP1121420A2 (en)	2001-08-08	Hepatitis a vaccines
US6488934B1 (en)	2002-12-03	Hepatitis B vaccine
US6620414B2 (en)	2003-09-16	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
KR20010043224A (ko)	2001-05-25	백신 조성물
CA2157376C (en)	2006-10-31	Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
AU705739B2 (en)	1999-06-03	A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A
CA2555911C (en)	2009-09-08	Adjuvant compositions containing 3-o deacylated monophosphoryl lipid a

Legal Events

Date	Code	Title	Description
2002-08-12	EEER	Examination request
2014-03-31	MKLA	Lapsed	Effective date: 20140217